{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:03:18Z","timestamp":1790352198475,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s10067-025-07348-5","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T12:09:17Z","timestamp":1738670957000},"page":"1113-1122","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effectiveness and safety of telitacicept in patients with systemic lupus erythematosus: a single center, retrospective, real-world study"],"prefix":"10.1007","volume":"44","author":[{"given":"Fang","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3160-5741","authenticated-orcid":false,"given":"Shuang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,4]]},"reference":[{"key":"7348_CR1","doi-asserted-by":"publisher","first-page":"e073980","DOI":"10.1136\/bmj-2022-073980","volume":"383","author":"EF Morand","year":"2023","unstructured":"Morand EF, Fernandez-Ruiz R, Blazer A, Niewold TB (2023) Advances in the management of systemic lupus erythematosus. BMJ 383:e073980. https:\/\/doi.org\/10.1136\/bmj-2022-073980","journal-title":"BMJ"},{"key":"7348_CR2","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1016\/S0140-6736(24)00398-2","volume":"403","author":"A Hoi","year":"2024","unstructured":"Hoi A, Igel T, Mok CC, Arnaud L (2024) Systemic lupus erythematosus. Lancet 403:2326\u20132338. https:\/\/doi.org\/10.1016\/S0140-6736(24)00398-2","journal-title":"Lancet"},{"key":"7348_CR3","doi-asserted-by":"publisher","unstructured":"Kiriakidou M, Ching CL (2020) Systemic lupus erythematosus. Ann Intern Med 172:ITC81-ITC96. https:\/\/doi.org\/10.7326\/AITC202006020","DOI":"10.7326\/AITC202006020"},{"key":"7348_CR4","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/art.40396","volume":"70","author":"S Karrar","year":"2018","unstructured":"Karrar S, Cunninghame Graham DS (2018) Abnormal B cell development in systemic lupus erythematosus: what the genetics tell us. Arthritis Rheumatol 70:496\u2013507. https:\/\/doi.org\/10.1002\/art.40396","journal-title":"Arthritis Rheumatol"},{"key":"7348_CR5","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1002\/art.41632","volume":"73","author":"PM Izmirly","year":"2021","unstructured":"Izmirly PM, Parton H, Wang L et al (2021) Prevalence of systemic lupus erythematosus in the United States: estimates from a meta-analysis of the Centers for Disease Control and Prevention National Lupus Registries. Arthritis Rheumatol 73:991\u2013996. https:\/\/doi.org\/10.1002\/art.41632","journal-title":"Arthritis Rheumatol"},{"key":"7348_CR6","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1097\/BOR.0000000000000480","volume":"30","author":"G Stojan","year":"2018","unstructured":"Stojan G, Petri M (2018) Epidemiology of systemic lupus erythematosus: an update. Curr Opin Rheumatol 30:144\u2013150. https:\/\/doi.org\/10.1097\/BOR.0000000000000480","journal-title":"Curr Opin Rheumatol"},{"key":"7348_CR7","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/ard-2022-223035","volume":"82","author":"J Tian","year":"2023","unstructured":"Tian J, Zhang D, Yao X, Huang Y, Lu Q (2023) Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study. Ann Rheum Dis 82:351\u2013356. https:\/\/doi.org\/10.1136\/ard-2022-223035","journal-title":"Ann Rheum Dis"},{"key":"7348_CR8","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1177\/0961203317726375","volume":"27","author":"X Ng","year":"2018","unstructured":"Ng X, dosReis S, Beardsley R, Magder L, Mullins CD, Petri M (2018) Understanding systemic lupus erythematosus patients\u2019 desired outcomes and their perceptions of the risks and benefits of using corticosteroids. Lupus 27:475\u2013483. https:\/\/doi.org\/10.1177\/0961203317726375","journal-title":"Lupus"},{"key":"7348_CR9","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1136\/ard.2006.068676","volume":"66","author":"GS Alarcon","year":"2007","unstructured":"Alarcon GS, McGwin G, Bertoli AM et al (2007) Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis 66:1168\u20131172. https:\/\/doi.org\/10.1136\/ard.2006.068676","journal-title":"Ann Rheum Dis"},{"key":"7348_CR10","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1177\/09612033231177296","volume":"32","author":"J Birt","year":"2023","unstructured":"Birt J, Delbecque L, O\u2019Brien D et al (2023) Real-world treatment patterns of immunosuppressants in adults with systemic lupus erythematosus: a claims database analysis in the United States. Lupus 32:815\u2013826. https:\/\/doi.org\/10.1177\/09612033231177296","journal-title":"Lupus"},{"key":"7348_CR11","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1093\/aje\/kws130","volume":"176","author":"LS Magder","year":"2012","unstructured":"Magder LS, Petri M (2012) Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. Am J Epidemiol 176:708\u2013719. https:\/\/doi.org\/10.1093\/aje\/kws130","journal-title":"Am J Epidemiol"},{"key":"7348_CR12","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1710-1492-9-30","volume":"9","author":"D Liu","year":"2013","unstructured":"Liu D, Ahmet A, Ward L et al (2013) A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol 9:30. https:\/\/doi.org\/10.1186\/1710-1492-9-30","journal-title":"Allergy Asthma Clin Immunol"},{"key":"7348_CR13","doi-asserted-by":"publisher","first-page":"e002701","DOI":"10.1136\/rmdopen-2022-002701","volume":"8","author":"A Floris","year":"2022","unstructured":"Floris A, Chessa E, Sebastiani GD et al (2022) Glucocorticoid tapering and associated outcome in patients with newly diagnosed systemic lupus erythematosus: the real-world GULP prospective observational study. RMD Open 8:e002701. https:\/\/doi.org\/10.1136\/rmdopen-2022-002701","journal-title":"RMD Open"},{"key":"7348_CR14","doi-asserted-by":"publisher","first-page":"6578","DOI":"10.3390\/ijms24076578","volume":"24","author":"D Accapezzato","year":"2023","unstructured":"Accapezzato D, Caccavale R, Paroli MP et al (2023) Advances in the pathogenesis and treatment of systemic lupus erythematosus. Int J Mol Sci 24:6578. https:\/\/doi.org\/10.3390\/ijms24076578","journal-title":"Int J Mol Sci"},{"key":"7348_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/08830185.2016.1276903","volume":"36","author":"E Samy","year":"2017","unstructured":"Samy E, Wax S, Huard B, Hess H, Schneider P (2017) Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases. Int Rev Immunol 36:3\u201319. https:\/\/doi.org\/10.1080\/08830185.2016.1276903","journal-title":"Int Rev Immunol"},{"key":"7348_CR16","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2020-217101","volume":"79","author":"HI Brunner","year":"2020","unstructured":"Brunner HI, Abud-Mendoza C, Viola DO et al (2020) Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. Ann Rheum Dis 79:1340\u20131348. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217101","journal-title":"Ann Rheum Dis"},{"key":"7348_CR17","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s40265-021-01591-1","volume":"81","author":"S Dhillon","year":"2021","unstructured":"Dhillon S (2021) Telitacicept: first approval. Drugs 81:1671\u20131675. https:\/\/doi.org\/10.1007\/s40265-021-01591-1","journal-title":"Drugs"},{"key":"7348_CR18","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1136\/ard-2023-224854","volume":"83","author":"D Wu","year":"2024","unstructured":"Wu D, Li J, Xu D et al (2024) Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 83:475\u2013487. https:\/\/doi.org\/10.1136\/ard-2023-224854","journal-title":"Ann Rheum Dis"},{"key":"7348_CR19","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/art.1780400928","volume":"40","author":"MC Hochberg","year":"1997","unstructured":"Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725. https:\/\/doi.org\/10.1002\/art.1780400928","journal-title":"Arthritis Rheum"},{"key":"7348_CR20","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","volume":"78","author":"M Aringer","year":"2019","unstructured":"Aringer M, Costenbader K, Daikh D et al (2019) 2019 European League against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis 78:1151\u20131159. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214819","journal-title":"Ann Rheum Dis"},{"key":"7348_CR21","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1177\/09612033221141253","volume":"32","author":"R Chen","year":"2023","unstructured":"Chen R, Fu R, Lin Z, Huang C, Huang W (2023) The efficacy and safety of telitacicept for the treatment of systemic lupus erythematosus: a real life observational study. Lupus 32:94\u2013100. https:\/\/doi.org\/10.1177\/09612033221141253","journal-title":"Lupus"},{"key":"7348_CR22","doi-asserted-by":"publisher","first-page":"e001074","DOI":"10.1136\/lupus-2023-001074","volume":"10","author":"HZ Jin","year":"2023","unstructured":"Jin HZ, Li YJ, Wang X et al (2023) Efficacy and safety of telitacicept in patients with systemic lupus erythematosus: a multicentre, retrospective, real-world study. Lupus Sci Med 10:e001074. https:\/\/doi.org\/10.1136\/lupus-2023-001074","journal-title":"Lupus Sci Med"},{"key":"7348_CR23","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1177\/09612033231208844","volume":"32","author":"C Cetin","year":"2023","unstructured":"Cetin C, Sarac-Sivrikoz T, Ates-Tikiz M et al (2023) The correlation between pregnancy, disease activity and adverse pregnancy outcomes in patients with systemic lupus erythematosus. Lupus 32:1509\u20131517. https:\/\/doi.org\/10.1177\/09612033231208844","journal-title":"Lupus"},{"key":"7348_CR24","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1097\/BOR.0000000000000527","volume":"30","author":"A Ugarte","year":"2018","unstructured":"Ugarte A, Danza A, Ruiz-Irastorza G (2018) Glucocorticoids and antimalarials in systemic lupus erythematosus: an update and future directions. Curr Opin Rheumatol 30:482\u2013489. https:\/\/doi.org\/10.1097\/BOR.0000000000000527","journal-title":"Curr Opin Rheumatol"},{"key":"7348_CR25","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.3390\/jcm12113639","volume":"12","author":"E Enriquez-Merayo","year":"2023","unstructured":"Enriquez-Merayo E, Cuadrado MJ (2023) Steroids in Lupus: Enemies or Allies. J Clin Med 12:3639. https:\/\/doi.org\/10.3390\/jcm12113639","journal-title":"J Clin Med"},{"key":"7348_CR26","doi-asserted-by":"publisher","first-page":"i22","DOI":"10.1093\/rheumatology\/keac678","volume":"62","author":"J He","year":"2023","unstructured":"He J, Li Z (2023) Dilemma of immunosuppression and infection risk in systemic lupus erythematosus. Rheumatology (Oxford) 62:i22\u2013i29. https:\/\/doi.org\/10.1093\/rheumatology\/keac678","journal-title":"Rheumatology (Oxford)"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07348-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07348-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07348-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T08:21:34Z","timestamp":1740558094000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07348-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,4]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["7348"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07348-5","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,4]]},"assertion":[{"value":"24 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}